Tavapadon
- Generic Name
- Tavapadon
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H16F3N3O3
- CAS Number
- 1643489-24-0
- Unique Ingredient Identifier
- PT4P8MJP8L
- Background
Tavapadon is under investigation in clinical trial NCT02262767 (A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy Subjects).
- Associated Conditions
- -
- Associated Therapies
- -
AbbVie's monotherapy achieves positive phase 3 results
AbbVie's tavapadon, a D1/D5 partial agonist, met primary and secondary endpoints in Phase 3 TEMPO-2 trial for early Parkinson's disease, showing significant improvements in movement and daily living aspects. Tavapadon aims to offer efficacy with fewer side effects compared to D2/D3 agonists.
AbbVie's Phase III trial of Parkinson's disease treatment meets primary endpoint
AbbVie's Phase III TEMPO-2 trial of tavapadon met primary endpoint, showing significant motor function improvements in early-stage Parkinson's disease patients. The trial achieved key secondary endpoints and maintained a consistent safety profile. AbbVie plans to submit an NDA to the FDA next year.
AbbVie Logs Another Phase III Success With Tavapadon In Parkinson's
AbbVie announces another successful Phase III trial for tavapadon, a D1/D5 dopamine receptor agonist for Parkinson’s, planning US FDA approval in 2025, potentially salvaging value from Cerevel buyout.
AbbVie's third successful Parkinson's trial sets the stage for an eventful 2025
AbbVie announced positive Phase 3 trial results for tavapadon, a Parkinson's disease treatment, meeting primary and secondary endpoints. The company plans to seek FDA approval in 2025.
AbbVie drug succeeds in another Parkinson's trial
Terry Pirovolakis developed a gene therapy for his son's ultra-rare disease SPG50 and founded Elpida Therapeutics to help other families. AbbVie's tavapadon showed success in another Parkinson's Phase 3 trial. The BIOSECURE Act, aimed at preventing U.S. biopharma companies from working with Chinese 'companies of concern,' was excluded from the defense budget bill. President-elect Trump echoed Robert F. Kennedy Jr.'s vaccine skepticism. A study highlighted disparities in bone marrow transplant access based on socioeconomic status.
AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating ...
AbbVie announces positive Phase 3 TEMPO-2 trial results for tavapadon, a D1/D5 partial agonist, showing significant improvement in MDS-UPDRS Parts II and III scores at week 26, meeting primary and key secondary endpoints. AbbVie plans to submit an NDA to the FDA in 2025.
AbbVie's Parkinson's Drug Tavapadon Shows Breakthrough Results in Phase 3 Trial
Tavapadon met primary and secondary endpoints in Phase 3 TEMPO-2 trial, showing significant improvement in MDS-UPDRS Parts II and III scores at week 26, supporting its potential as a first-in-class D1/D5 partial agonist for Parkinson's disease. AbbVie plans to submit an NDA to the FDA in 2025.
AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
The site uses cookies for service delivery. By using it, users acknowledge understanding of the Cookie Policy, Privacy Policy, and Terms of Use.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath